Enanta Pharmaceuticals | Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Amgen USD 539M 1000K 2025-12
Anika Therapeutics USD 143K 1000 2025-03
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 206K 2025-12
BioCryst Pharmaceuticals USD 1.9M 3K 2023-09
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 1.52M 14K 2024-09
Immunic USD 8K 4K 2024-06
Incyte USD 198.46M 2.33M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
J&J USD 2.41B 584K 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.49B 15.79M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.94B 23.4M 2025-06
Novavax USD 1.62M 211K 2024-09
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12


Enanta Pharmaceuticals Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2026.